Results 111 to 120 of about 2,950,121 (263)

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure. [PDF]

Front Artif Intell
Yang L, Bryan ME, Veiga E, Lowenhoff I, Wan A, Mina I, Allen T, Alfaro JA, Bloomfield G, Beach J, Dahlgren K, Davis NK, Fontana E, Gennatas S, Ghafoor Q, Housseau F, Lubelski D, Zhang Z, Hancock M, Ince W, James D, Khan S, Kunene V, McGrane J, Millen GC, Moxley-Wyles B, Narganes-Carlon D, Payne M, Ross PJ, Roux R, Rowe M, Lee R, Lee JSH, Liu JKH, Aggarwal D, Teoh ABS, Thirlwell C, Tilby M, Symeonides S, Watts I, Agus DB, Ono SJ, Elliott T, Calleja P, Lee LYW.   +44 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Effect of Parity and β-Amyloid on Cognition and Hippocampal Volume in Postmenopausal Women. [PDF]

Neurology
Gallay C, Soldevila-Domenech N, López-Martos D, Sanchez-Benávides G, Huguet J, Suárez-Calvet M, Gispert JD, Salvadó G, Sundermann EE, Grau-Rivera O, Brugulat-Serrat A, for ALFA study.   +11 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

LCR-modules: a collection of workflows for cancer genome analysis. [PDF]

Bioinformatics
Dreval K, Hilton LK, Grande BM, Banco G, Coyle KM, Cruz M, Gillis S, Klossok L, Pararajalingam P, Rushton CK, Shaalan H, Thomas N, Winata H, Wong J, Yiu J, Steidl C, Scott DW, Morin RD.   +17 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Neuropathy predicts early renal impairment in diabetes mellitus-the almost forgotten historical evidence. In memoriam Professor Göran Sundkvist. [PDF]

Front Clin Diabetes Healthc
Kempler P, Balogh DM, Horváth VJ, Menyhárt A, Rizzo M, Tesfaye S, Spallone V.   +6 more
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source